Pharma & Life-Sciences Software Licensing

What you will take away

• Validation, not seats: why GxP status and validated-environment chains dominate licensing economics in pharma.
• CSV to CSA: how the risk-based Computer Software Assurance shift changes the cost of every system you license.
• The environment multiplier: how prod, validation, non-prod and DR chains turn one license into four cost centres.
• System sprawl: where LIMS, MES, QMS, eTMF, RIM, PV, CTMS and serialization each hide their own licensing and validation burden.
• Over-scoped Part 11: the systematic over-buy patterns an independent buyer-side review reliably recovers.